Overall, the disruption of PI3K/AKT/mTOR signaling has been implicated in cancer, immunological disorders, diabetes, and cardiovascular disease, and led to the development of therapies targeted at PI3K pathways. This evidence concerns the gene PIK3CA and cancer.